Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa Biosciences (NASDAQ: ANIX) announced that its collaborator, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for a patent application on breast cancer vaccine technology. This extends the patent protection to Japan, in addition to existing U.S. and European patents. Anixa is the exclusive worldwide licensee of this technology.
The vaccine, currently in phase one clinical trials at Cleveland Clinic, targets α-lactalbumin, a breast-specific lactation protein present in certain breast cancers but not in normal aging tissues post-lactation. By activating the immune system against this 'retired' protein, the vaccine aims to provide preemptive protection against emerging breast tumors expressing α-lactalbumin.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company focused on cancer treatment and prevention, has announced a $5 million share repurchase program. The program, authorized by the Board of Directors, allows for the repurchase of outstanding common stock over a 12-month period. Dr. Amit Kumar, Chairman and CEO, stated that this decision reflects confidence in the company's future outlook, balance sheet strength, and clinical development pipeline. He also expressed the belief that Anixa's stock is currently undervalued.
The repurchases will be made through open-market transactions in compliance with securities laws. The program can be suspended or discontinued at any time, and no shares have been repurchased to date. This initiative aims to enhance long-term shareholder value.
Anixa Biosciences has treated the sixth and final patient in the second dosage cohort of its Phase 1 clinical trial for an ovarian cancer CAR-T therapy, partnered with Moffitt Cancer Center. If no adverse effects are observed, the third dosage cohort, with a tenfold increase in dose, may commence next month. The trial focuses on evaluating the safety and efficacy of Anixa's FSHR-targeting CAR-T technology. The first cohort showed no dose-limiting toxicities, and a notable response from one patient was observed despite the subtherapeutic dose. The second cohort, receiving triple the initial dose, also reported no dose-limiting toxicities. The therapy involves intraperitoneal delivery, which potentially minimizes side effects and enhances targeting efficacy.
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor (FSHR), which is uniquely expressed on ovarian cells. Safety was confirmed in the first cohort of three patients, and the second cohort, including the fifth patient, receives triple the dose of engineered T-cells. According to Dr. Amit Kumar, Anixa's Chairman and CEO, the trial continues to show that the therapy is safe and well-tolerated, offering hope for an effective CAR-T treatment for solid tumors.
Anixa Biosciences, a clinical-stage biotechnology company, announced an expanded partnership with Cleveland Clinic to develop novel cancer vaccines targeting various cancer types. The vaccines focus on a unique scientific approach by immunizing against 'retired' proteins found in cancer cells, aiming to destroy cancer cells as they arise and prevent tumor formation. Collaborating on breast cancer and ovarian cancer vaccines, the partnership aims to lead in cancer research with promising preliminary data.
Anixa Biosciences, Inc. CEO Dr. Amit Kumar was featured on the 'Target: Cancer Podcast' by oncologist Dr. Sanjay Juneja, discussing 'The Vaccine That Could End Breast Cancer.' The podcast highlighted Anixa's unique vaccine technology aiming to prevent the growth and spread of cancer cells. Dr. Juneja praised the potential impact of Anixa's vaccines on cancer treatment.
Anixa Biosciences, a clinical-stage biotechnology company, will participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024. The CEO will present the company's cancer treatment and prevention programs, including a breast cancer vaccine in Phase 1 trials and a CAR-T cell therapy for ovarian cancer in Phase 1 trials. The company has a capital efficient business model with strong positive data and no debt.
Summary not available.
Summary not available.
Summary not available.